The European Commission has approved Susvimo, a new treatment for neovascular age-related macular degeneration (nAMD). This condition is a major cause of vision loss in individuals over 60. Susvimo offers continuous delivery of medication directly into the eye via the Contivue refillable implant. This innovative system provides an alternative to frequent eye injections, significantly reducing the treatment burden for patients. Clinical trials demonstrated that Susvimo maintained vision equivalent to monthly injections. With Susvimo, many patients require as few as two treatments per year. This continuous delivery aims to help patients maintain their vision more effectively. nAMD affects millions worldwide and can lead to rapid vision loss if untreated. Roche developed the Contivue Port Delivery Platform to facilitate this continuous drug delivery. The approval marks a significant advancement in nAMD treatment options for European patients.